Investigation of the Effects of Omega-3 Supplementation in Chronic Kidney Disease Patients Diagnosed With Coronary Artery Disease and Dyslipidemia

The intervention group will receive a daily oral supplementation of 2000 mg omega-3, which will not be administered to the control group. Blood samples will be collected from all participants at baseline and at the end of the study to evaluate selected serum parameters. To minimize nutritional variability, individualized diets appropriate for coronary artery disease and chronic kidney disease were prescribed to both groups at the beginning of the study. Unlike many other intervention studies, this trial specifically targets end-stage renal disease patients and includes an evaluation of the intervention's impact in relation to dialysis initiation.

Participants in the control group will not receive any dietary supplementation. Blood samples will be collected at baseline and at the end of the study to assess selected biochemical parameters. Standard dietary care appropriate for coronary artery disease and chronic kidney disease will be maintained throughout the study.